Drug Genetic Screening
Drug Genetic Screening - Related Videos
08:50
Genetic Screens
0 Views •
2023
Genetic screens are critical tools for defining gene function and understanding gene interactions. Screens typically involve mutating genes and then assessing the affected organisms for phenotypes of interest. The process can be “forward”, where mutations are generated randomly to identify unknown genes responsible for the phenotypes, or it can be “reverse”, where specific genes are targeted for mutation to observe what phenotypes are produced.Here, JoVE reviews various types of genetic...
02:46
Genetic Screens
0 Views •
2021
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options. Forward genetic screens Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
08:10
Multi-enzyme Screening Using a High-throughput Genetic Enzyme Screening System
0 Views •
Cited by 7 •
2016
This work presents a method of high-throughput screening using a universal genetic enzyme screening system that can be theoretically applied to over 200 enzymes. Here, the single screening system identifies three different enzymes (lipase, cellulase, and alkaline phosphatase) by simply changing the substrate used (p-nitrophenyl acetate, p-nitrophenyl-β-D-cellobioside, and phenyl phosphate).
08:17
VIGS-Mediated Forward Genetics Screening for Identification of Genes Involved in Nonhost Resistance
0 Views •
Cited by 22 •
2013
Virus-induced gene silencing is an useful tool for identifying genes involved in nonhost resistance of plants. We demonstrate the use of bacterial pathogens expressing GFPuv in identifying gene silenced plants susceptible to nonhost pathogens. This approach is easy, fast and facilitates large scale screening and similar protocol can be applied to studying various other plant-microbe interactions.
11:28
3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening
0 Views •
Cited by 7 •
2017
This protocol describes the fabrication of elastic 3D macroporous microcryogels by integrating microfabrication with cryogelation technology. Upon loading with cells, 3D microtissues are generated, which can be readily injected in vivo to facilitate regenerative therapy or assembled into arrays for in vitro high-throughput drug screening.
FAQs
The analysis focuses on DNA markers in three functional areas: genes affecting drug metabolism, transport, and molecular targets. Variants in these areas can alter how much medication reaches the body, how it is handled, or how it acts. This provides the biological basis for interpreting possible differences in treatment response.
A variant can influence medication exposure by affecting metabolism or transport. It may also influence effectiveness or the likelihood of adverse reactions through changes involving a drug target. Interpreting these possibilities helps connect a person’s genetic profile with relevant outcomes, including differences in medication levels and response.
Genetic information adds a person-specific biological layer to medication evaluation. Rather than considering only the medication and the condition being treated, clinicians can also consider markers related to how the drug is processed or acts. This context may support more informed choices about medication selection and dosing.
Behavioral and psychiatric care may involve medications intended to affect mood, cognition, or behavior. Genetic markers can provide additional context when clinicians evaluate these treatments, particularly when differences in medication levels, effectiveness, or adverse reactions are important. The results therefore connect pharmacogenomic information with treatment decisions in behavioral health.
The process begins with analysis of a person’s DNA markers, followed by consideration of genes linked to medication metabolism, transport, or drug targets. Clinicians then relate the genetic information to a particular treatment and its possible effects. This interpretation can inform medication selection or dosing during treatment evaluation.
Clinicians may consider the information when evaluating medications used for conditions affecting mood, cognition, or behavior. It can be especially relevant when treatment response, medication levels, or adverse reactions are part of the decision. The results support, rather than replace, informed evaluation of medication choices and dosing.
Drug genetic screening contributes to pharmacogenomic research by linking genetic variation with medication response. In behavioral science, this connection can be examined in relation to treatments affecting mood, cognition, or behavior. Such information helps researchers study why medication outcomes may differ among individuals and supports more individualized approaches to medication management.